Pharmaceuticals

Esketamine Market Forecast: What to Expect by 2029

November 10, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Are The Forecasted Market Size Estimates For The Esketamine Market Between 2025 And 2029?

The esketamine market has experienced significant expansion in recent years. Its value is projected to rise from $1.37 billion in 2024 to $1.51 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 9.9%. This past growth can be attributed to several factors including an increased patient count, the rising global prevalence of mental health disorders, better awareness of the disease state, a growing need for new therapeutic solutions, and supportive regulatory approvals.

The esketamine market is set to experience significant expansion in the upcoming years. Its value is projected to reach $2.26 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 10.7%. This growth over the forecast period is driven by several factors, including the increasing occurrence of treatment-resistant depression, heightened investment in research and development programs, a rising demand for smart healthcare infrastructure, the expanding trend of telehealth services, and the growing acceptance of esketamine as an effective therapeutic option. Notable trends anticipated during this period encompass partnerships between biotechnology firms and mental health organizations, the application of robotics in healthcare, personalized medicine strategies, the use of sensor-based devices, and the potential for combination therapies.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23393&type=smp

Which Drivers Are Impacting The Esketamine Market?

The increasing occurrence of treatment-resistant depression (TRD) is anticipated to propel the growth of the esketamine market in the coming years. Treatment-resistant depression (TRD) describes depression that does not improve after trying at least two different antidepressant medications at proper doses for a sufficient duration. The rise in treatment-resistant depression (TRD) is due to the limited effectiveness of conventional antidepressants, leading to prolonged and recurring depressive episodes. Esketamine helps treatment-resistant depression (TRD) by offering a fast-acting mechanism that targets the NMDA receptors, providing relief for patients who do not respond to traditional antidepressants. For instance, in September 2023, the National Institute of Mental Health (NIMH), a US-based federal agency, reported that, in 2023, about 30% of individuals with major depressive disorder in the U.S. are resistant to standard treatments. Therefore, the rising incidence of treatment-resistant depression is driving the growth of the esketamine market.

How Is The Esketamine Market Classified Into Different Segments?

The esketamine market covered in this report is segmented –

1) By Type: Oral Medications, Injection, Nasal Spray, Other Types

2) By Indication: Major Depressive Disorder, Chronic Pain, Post-Traumatic Stress Disorder, Anxiety Disorders

3) By Patient Type: Adult Patients, Pediatric Patients, Geriatric Patients

4) By Application: General Anesthetic, Treatment-Resistant Depression

5) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

Subsegments:

1) By Oral Medications: Immediate-Release Tablets, Extended-Release Tablets, Sublingual Tablets

2) By Injection: Intravenous Injection, Intramuscular Injection, Subcutaneous Injection

3) By Nasal Spray: Prescription Nasal Spray, Over-The-Counter Nasal Spray, Combination Therapy Nasal Spray

4) By Other Types: Plasmapheresis, Intravenous Immunoglobulin (IVIG) Therapy, Stem Cell Therapy

Which Ongoing Trends Are Expected To Shape The Esketamine Market Outlook?

Leading companies in the esketamine market are prioritizing the creation of advanced treatment solutions, such as monotherapy, to offer enhanced relief from depressive symptoms beyond what a placebo provides. Monotherapy signifies the application of a single drug or treatment to manage a disease or medical condition, instead of utilizing multiple therapies in combination. For example, in January 2025, Johnson & Johnson, a US-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had given its approval to SPRAVATO (esketamine) as the initial and sole monotherapy for adults diagnosed with treatment-resistant depression (TRD). Supported by clinical trials, this approval demonstrated SPRAVATO’s capacity to quickly lessen depressive symptoms, with considerable improvements noted within 24 hours. This innovation offers a crucial alternative for approximately 30% of individuals who do not respond to conventional antidepressants, thereby removing the necessity for concurrent oral medications. While SPRAVATO maintains a favorable safety profile, it is administered under a Risk Evaluation and Mitigation Strategy (REMS) to manage potential side effects. This accomplishment represents a significant progression in TRD treatment, instilling renewed hope for improved patient outcomes.

Who Are The Core Companies Influencing The Esketamine Market Landscape?

Major companies operating in the esketamine market are Cigna Corporation, Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Sigma-Aldrich Corporation, Horizon Therapeutics plc, Hikma Pharmaceuticals plc, Cerecor Inc., Celon Pharma S.A., Nortec Química S.A., XWPharma Ltd., Seqens Group, SynZeal Research Pvt. Ltd., Arevipharma GmbH, Sage Therapeutics Inc., Supriya Lifescience Ltd., Clexio Biosciences Ltd., Maithri Drugs Pvt. Ltd., VistaGen Therapeutics Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/esketamine-global-market-report

What Are The Key Regional Factors Influencing The Esketamine Market Growth?

North America was the largest region in the esketamine market in 2024. The regions covered in the esketamine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Esketamine Market Report:

https://www.thebusinessresearchcompany.com/customise?id=23393&type=smp

Browse Through More Reports Similar to the Global Esketamine Market 2025, By The Business Research Company

Inhalation And Nasal Spray Generic Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/inhalation-and-nasal-spray-generic-drugs-global-market-report

Antidepressant Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/antidepressant-global-market-report

Postpartum Depression Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/postpartum-depression-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795